Biomarkers in Patients With Head and Neck Cancer

ECOG-ACRIN Cancer Research Group

Status: Completed

Conditions: Head and Neck Cancer

Treatments: Genetic: mutation analysis; Other: laboratory biomarker analysis; Biological: cetuximab; Drug: cisplatin; Genetic: gene expression analysis; Genetic: DNA analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01466257

ECOG-E5397T2

CDR0000715520

Details and patient eligibility

About

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.

Full description

OBJECTIVES:

• To determine the mutation rates of HRAS and PIK3CA in patients with head and neck squamous cell carcinoma (HNSCC) who were treated with cisplatin/placebo and cisplatin/cetuximab on protocol ECOG-E5397.
• To determine the association between HRAS or PIK3CA mutation status and clinical benefits (i.e., response, progression-free survival, and overall survival) in patients treated with cisplatin/cetuximab compared with those receiving cisplatin/placebo on protocol ECOG-E5397.

OUTLINE: DNA is isolated from one unstained slide per patient. The mutations in HRAS and PIK3CA are determined using BEAMING technology.

Enrollment: 70 patients

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Treated on protocol ECOG-E5397

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics